Protego Biopharma closed an oversubscribed $130 million Series B to finance PROT-001, its oral candidate for AL (light-chain) amyloidosis, and to support a planned pivotal study. The round was led by established and new investors including Novartis Venture Fund and Forbion. Protego said the financing extends its runway and enables the company to move into a trial intended to establish registrational data. The company positions PROT-001 as a first-in-class small molecule intended to stabilize pathogenic light chains — a mechanistic contrast to recent antibody failures in the field. Backers include investors with rare-disease track records; success in a pivotal would put Protego directly in competition with late-stage programs and shape funding appetite for oral stabilizer strategies.